SEARCH

SEARCH BY CITATION

References

  • 1
    Wilkinson IB, MacCallum H, Flint L, et al. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000;525:263270.
  • 2
    Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;7:118123.
  • 3
    Mackenzie IS, McEniery CM, Dhakam Z, et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension. 2009;54:409413.
  • 4
    London GM, Asmar RG, O'Rourke MF, Safar ME. Reason Project Investigators. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004;43:9299.
  • 5
    Williams B, Lacy PS, Thom SM, et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:12131225.
  • 6
    Agabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag. 2009;5:353360.
  • 7
    Dhakam Z, Yasmin, McEniery CM, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008;26:351356.
  • 8
    Mahmud A, Feely J. Β-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008;21:663667.
  • 9
    Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57:11221128.
  • 10
    Jabbour A, Macdonald PS, Keogh AM, et al. Differences between β-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:17801787.
  • 11
    Shah NK, Smith SM, Nichols WW, et al. Carvedilol reduces aortic wave reflection and improves left ventricular/vascular coupling: a comparison with atenolol (CENTRAL Study). J Clin Hypertens (Greenwich). 2011;13:917924.
  • 12
    Barna I, Keszei A, Dunai A. Evaluation of Meditech ABPM-04 ambulatory blood pressure measuring device according to the British Hypertension Society protocol. Blood Press Monit. 1998;3:363368.
  • 13
    Salvi P, Lio G, Labat C, et al. Validation of a new non-invasive portable tonometer for determining arterial pressure wave and pulse wave velocity: the PulsePen device. J Hypertens. 2004;22:22852293.
  • 14
    El AM, Topouchian J, Asmar R. Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT. Blood Press Monit. 2003;8:127133.
  • 15
    Laurent S, Cockcroft J, Van BL, et al. European Network for Non-invasive Investigation of Large Arteries: expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:25882605.
  • 16
    Takazawa K, Tanaka N, Takeda K, et al. Underestimation of vasodilator effects of nitroglycerin by upper limb blood pressure. Hypertension. 1995;26:520523.
  • 17
    Murgo JP, Westerhof N, Giolma JP, Altobelli SA. Aortic input impedance in normal man: relationship to pressure wave forms. Circulation. 1980;62:105116.
  • 18
    Westerhof BE, Guelen I, Westerhof N, et al. Quantification of wave reflection in the human aorta from pressure alone: a proof of principle. Hypertension. 2006;48:595601.
  • 19
    Liao CF, Cheng HM, Sung SH, et al. Determinants of pressure wave reflection: characterization by the transit time-independent reflected wave amplitude. J Hum Hypertens. 2011;25:665671.
  • 20
    Davis JT, Pasha DN, Khandrika S, et al. Central hemodynamics in prehypertension: effect of the β-adrenergic antagonist nebivolol. J Clin Hypertens (Greenwich). 2013;15:6974.
  • 21
    Tham TC, Guy S, McDermott BJ, et al. The dose dependency of the alpha- and β-adrenoceptor antagonist activity of carvedilol in man. Br J Clin Pharmacol. 1995;40:1923.
  • 22
    Goldberger JJ. Sympathovagal balance: how should we measure it? Am J Physiol. 1999;276:H1273H1280.
  • 23
    Zepeda RJ, Castillo R, Rodrigo R, et al. Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension. Basic Clin Pharmacol Toxicol. 2012;111:309316.
  • 24
    Xiaozhen H, Yun Z, Mei Z, Yu S. Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. Blood Press. 2010;19:4047.
  • 25
    Nishiyama K, Tsutamoto T, Yamaji M, et al. Dose-dependent prognostic effect of carvedilol in patients with chronic heart failure–special reference to transcardiac gradient of norepinephrine. Circ J. 2009;73:22702275.